Cognitive Impairment Pipeline Review, H2 2016 - 53 Companies & 119 Molecules - Research and Markets

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Cognitive Impairment - Pipeline Review, H2 2016" report to their offering.

Cognitive Impairment - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Cognitive Impairment and features dormant and discontinued projects.

Cognitive Impairment Cognitive impairment, also referred to as intellectual disability, describes the condition of a person who has trouble in remembering, learning new things, concentrating, or making decisions that affect their everyday life. Symptoms include memory loss, vision problems, depression, irritability and aggression, anxiety and apathy. The predisposing factors include age, sex, family history and other major risk factors (hypertension, hypercholesterolemia, diabetes mellitus and tobacco) known to be associated frequently with different cerebrovascular diseases, might also contribute to degenerative forms of cognitive impairment.

Cognitive Impairment pipeline therapeutics constitutes close to 119 molecules. Out of which approximately 109 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 15, 25, 2, 53, 11 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 7 and 1 molecules, respectively.

Key Topics Covered:

1. Introduction
2. Cognitive Impairment Overview
3. Therapeutics Development
4. Pipeline Products for Cognitive Impairment - Overview
5. Pipeline Products for Cognitive Impairment - Comparative Analysis
6. Cognitive Impairment - Therapeutics under Development by Companies
7. Cognitive Impairment - Therapeutics under Investigation by Universities/Institutes
8. Cognitive Impairment Products Glance
9. Late Stage Products
10. Clinical Stage Products
11. Early Stage Products
12. Cognitive Impairment - Products under Development by Companies
13. Cognitive Impairment - Products under Investigation by Universities/Institutes
14. Cognitive Impairment - Companies Involved in Therapeutics Development

• AbbVie Inc
• Addex Therapeutics Ltd
• AgeneBio Inc.
• Amarantus Bioscience Holdings, Inc.
• Astellas Pharma Inc.
• AstraZeneca Plc
• Avraham Pharmaceuticals Ltd.
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb Company
• Cognition Therapeutics, Inc.
• Confluence Pharmaceuticals LLC
• Coronis Partners Ltd.
• Cortice Biosciences, Inc.
• Eisai Co., Ltd.
• Eli Lilly and Company
• Ensol Biosciences Inc.
• FORUM Pharmaceuticals Inc.
• Luc Therapeutics, Inc.
• Merck & Co., Inc.
• Nanotherapeutics, Inc.
• Neuralstem, Inc.
• Neuron Biopharma SA
• NLS Pharma Group
• Octapharma AG
• Omeros Corporation
• Pacific Northwest Biotechnology, LLC
• Panacea Pharmaceuticals, Inc.
• Pfizer Inc.
• Pherin Pharmaceuticals, Inc.
• Takeda Pharmaceutical Company Limited
• Tetra Discovery Partners LLC
• Therapix Biosciences Ltd.
• Vanda Pharmaceuticals Inc.
• Vicore Pharma AB
• Virogenomics BioDevelopment, Inc.

For more information about this report visit http://www.researchandmarkets.com/research/mw2f78/cognitive